CAMP4 receives UK authorization for its first SYNGAP1 clinical study
CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, while European Union submissions remain under review. The company expects to begin first-in-human dosing in the fourth quarter of 2026. CMP002 is an antisense-oligonucleotide candidate designed to act on regulatory RNA and increase production of the relevant pro
0